; (4) the manufacturer, subject to subsection (c), submits to the Secretary, in a form and manner specified by the Secretary— (A) for the voluntary negotiation period for the price applicability period (and, if applicable, before any period of renegotiation specified pursuant to paragraph (2)) with respect to such drug all information that the Secretary requires to carry out the negotiation (or renegotiation process) under this part, including information described in section 1192(f) and section 1194(d)(1); and (B) on an ongoing basis, information on changes in prices for the drug that would affect the AIM price for the drug or otherwise provide a basis for renegotiation of the maximum fair price of such drug pursuant to paragraph (2); (5) the manufacturer agrees that in the case the selected drug of a manufacturer is a drug described in subsection (c), the manufacturer will, in accordance with such subsection, make any payment required under such subsection with respect to such drug